Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro

Transplant Immunology

Volumn 4, Issue 2, 1996, Pages 117-125

  Östraat, Öyvind ^a,c   Riesbeck, Kristian ^a,b   Qi, Zhongquan ^a   Eriksson, Tommy ^a   Schatz, Hanna ^a   Ekberg, Henrik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MIXED LYMPHOCYTE CULTURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RAT; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0030174891     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80005-0     Document Type: Article

References (44)

1. Sheskin J. Thalidomide in treatment of lepra reactions. Clin Pharmacol Ther. 6:1965;303-306.
2. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol. 118:1982;536.
3. Knop J, Bonsman G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 146:1983;878-881.
4. Waters M.F.R, Laing A.B.G, Ambikapathy A, Lennard-Jones J.E. Treatment of ulcerative colitis with thalidomide. Br Med J. 6166:1979;792.
5. Georghiou P.R, Allworth A.M. Thalidomide in painful AIDS-associated proctitis. J Infect Dis. 166:1992;939-940.
6. Ghigliotti G, Repetto T, Farris A, Roy M.T, De Marchi R. Thalidomide: treatment of choice for aphthous ulcers in patients seropositive for immunodeficiency virus. J Am Acad Dermatol. 28:1993;271-272.
7. Hellmann K, Duyke D.J, Tucker D.F. Prolongation of skin homograft survival by Thalidomide. Br Med J. 2:1965;687-689.
8. Murphy G.P, Brede H.D, Weber H.W, Groenewald J.H, Williams P.D. Thalidomide immunosuppression in canine renal allotransplantation. J Med. 1:1970;66-73.
9. Vogelsang G.B, Wells M.C, Santos G.W, Chen T.L, Hess A.D. Combination low-dose thalidomide and cyclosporin prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc. 2:1988;226-228.
10. Vogelsang G.B, Hess A.D, Gordon G, Santos G.W. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation. 5:1986;644-647.
11. Tamura F, Vogelsang G.B, Reitz B.A, Baumgartner W.A, Herskowitz A. Combination thalidomide and cyclosporin for cardiac allograft rejection. Transplantation. 1:1990;20-25.
12. Emre S, Sumrani N, Hong J. Beneficial effect of thalidomide and ciclosporin combination in heterotopic cardiac transplantations in rats. Eur Surg Res. 22:1990;336-339.
13. Gad S.M, Shannon E.J, Krotosk W.A, Hastings R.C. Thalidomide produces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev. 56:1985;35-39.
14. Moncada B, Baranada M.L, Gonzalez-Amaro R, Urbina R, Loredo C.E. Thalidomide-effect on T cell subsets as a possible mechanism of actions. Int J Lepr. 2:1985;201-205.
15. Sampaio E.P, Sarno E.N, Galilly R, Cohn Z.A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 173:1991;699-703.
16. Makonkawkeyoon S, Limson-Pobre R.N.R, Moreira A.L, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 90:1993;5974-5978.
17. Neubert R, Nogueira A.C, Neubert D. Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol. 67:1993;1-17.
18. Neubert R, Nogueira A.C, Neubert D. Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci. 26:1992;2107-2116.
19. Guston J.P, Cohen C. Effect of thalidomide on the antibody response. Am J Obstet Gynecol. 7:1968;952-956.
20. Coulsson A.S, Summers L.J, Lindahl-Kiessling K, Tucker D, Hellman K. The effect of two soluble thalidomide derivatives on lymphocyte stimulation. Clin Exp Immunol. 7:1970;241-247.
21. Roath S, Elves M.W, Israels M.C.G. Effects of thalidomide on leucocyte cultures. Lancet. ii:1962;812-813.
22. Roath S, Elves M.W, Israels M.C.G. Effects of thalidomide and its derivatives on human leucocytes cultured in vitro. Lancet. ii:1963;249-250.
23. Keenan R.J, Eiras G, Burckart G.J, Stuart R.S, et al. Immunosuppressive properties of thalidomide. Transplantation. 52:1991;908-910.
24. Gordon G.B, Spielberg S.P, Blake D.A, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA. 78:1981;2545-2548.
25. Braun A.G, Weinreb S.L. Teratogen metabolism: activation of thalidomide and thalidomide analogues to products that inhibit the attachment of cells to concavalin a coated plastic surfaces. Biochem Pharmacol. 33:1984;1471-1477.
26. Hatfill S.J, Fester E.D, De Beer D.P, Bohm L. Induction of morphological differentiation in the human leukemic line K562 by exosure to thalidomide metabolites. Leuk Res. 15:1991;129-136.
27. Riesbeck K, Sigvardsson M, Leandersson T, Forsgren A. Superinduction of cytokine gene transcription by ciprofloxacin. J Immunol. 153:1994;343-352.
28. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
29. Fourney R.M, Miyakoshi J, Day R.S III, Paterson M. Northern blotting: efficient RNA staining and transfer. Focus. 10:1988;5-8.
30. Maron D.M, Ames B.N. Revised method for the Salmonella mutagenicity test. Mutat Res. 113:1983;173-215.
31. Eriksson T, Björkman S, Fyge Å, Ekberg H. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr. 582:1992;211-216.
32. Woo J, Ross C.S.K, Milton J.I, Thomson A.W. Immunosuppressive activity of FK 506 in rats: flow cytometry analysis of lymphocyte population in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol. 79:1990;109-113.
33. Olausson M, Mjörnstedt L, Lindholm L, Brynger H. Nonsuture organ grafting to neck vessels in rat. Acta Chir Scand. 15:1984;463-467.
34. June C.H, Ledbetter J.A, Gillespie M.M, Lindsten T, Thompson C.B. Mol Cell Biol. 12:1987;4472-4481.
35. Williams T.M, Moolten D.M, Makni H, Kim H.W, Kant L.A, Kamoun M. CD28-stimulated IL-2 gene expression in Jurkat T cells occurs in part transcriptionally and is cyclosporine-A sensitive. J Immunol. 148:1992;2609-2616.
36. Eriksson T, Riesbeck K, Östraat Ö, Ekberg H, Björkman S. Drug exposure and flow cytometry analyses in a thalidomide treatment schedule that prolongs rat cardiac graft survival. Transplant Proc. 6:1992;2560-2561.
37. Vogelsang G.B, Hess A.D, Santos G.W. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant. 3:1988;393-398.
38. Shokes D.A, Wook K.J. Indirect presentation of MHC antigens in transplantation. Immunol Today. 15:1994;32-38.
39. Shizuru J.A, Seydel K.B, Flavin T.F, et al. Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti CD4 monoclonal antibody therapy. Transplantation. 50:1990;366-373.
40. Sampaio E.P, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 168:1993;408-414.
41. Moreira A.L, Sampaio E.P, Zmuidzinas A, Frindt P, Smith K.A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med. 177:1993;1675-1680.
42. Tsuchida A, Salem H, Thomson N, Hancock W.W. Tumour necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression. J Exp Med. 175:1992;81-90.
43. Lin H, Chensue S, Strieter R.M, et al. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. J Heart Lung Transplant. 11:1992;330-335.
44. Vassali P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 10:1992;411-452.